IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.503
AS - Asia 3.931
EU - Europa 3.285
SA - Sud America 646
AF - Africa 109
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.484
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.374
SG - Singapore 1.864
IT - Italia 993
IE - Irlanda 579
CN - Cina 561
BR - Brasile 496
HK - Hong Kong 466
VN - Vietnam 404
RU - Federazione Russa 400
DE - Germania 240
FR - Francia 197
FI - Finlandia 170
SE - Svezia 138
KR - Corea 132
UA - Ucraina 130
GB - Regno Unito 120
IN - India 110
MX - Messico 56
AR - Argentina 54
BD - Bangladesh 54
CA - Canada 54
RO - Romania 53
TR - Turchia 50
AT - Austria 44
NL - Olanda 42
IQ - Iraq 35
UZ - Uzbekistan 35
BE - Belgio 33
PL - Polonia 32
PK - Pakistan 30
ZA - Sudafrica 28
JP - Giappone 25
CZ - Repubblica Ceca 22
ID - Indonesia 22
PH - Filippine 22
ES - Italia 21
CO - Colombia 20
CH - Svizzera 18
EC - Ecuador 18
LT - Lituania 17
SA - Arabia Saudita 17
VE - Venezuela 16
EG - Egitto 15
PE - Perù 14
JO - Giordania 12
MA - Marocco 11
CL - Cile 9
ET - Etiopia 9
AZ - Azerbaigian 8
KE - Kenya 8
MY - Malesia 8
CI - Costa d'Avorio 7
IL - Israele 7
IR - Iran 7
KZ - Kazakistan 7
LB - Libano 7
NP - Nepal 7
PY - Paraguay 7
TH - Thailandia 7
TN - Tunisia 7
UY - Uruguay 7
AL - Albania 6
PT - Portogallo 6
BO - Bolivia 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
CR - Costa Rica 4
PA - Panama 4
SC - Seychelles 4
AO - Angola 3
AU - Australia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GR - Grecia 3
JM - Giamaica 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
DZ - Algeria 2
EU - Europa 2
HR - Croazia 2
IM - Isola di Man 2
KH - Cambogia 2
LV - Lettonia 2
MK - Macedonia 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
SN - Senegal 2
TW - Taiwan 2
UG - Uganda 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 12.462
Salva come PNG Salva come JPEG
Città #
Singapore 1.392
Chandler 594
Dublin 572
San Jose 490
Perugia 487
Hong Kong 466
San Mateo 384
Ashburn 308
Boardman 207
Santa Clara 176
Dong Ket 140
Altamura 131
Lauterbourg 131
Moscow 129
Seoul 129
Munich 117
Medford 107
Princeton 105
Lawrence 101
Beijing 100
Ho Chi Minh City 86
Ann Arbor 81
New York 74
Los Angeles 72
Hanoi 66
Wilmington 66
Andover 63
Helsinki 63
Jacksonville 59
Turku 56
Piscataway 48
The Dalles 48
São Paulo 45
Bucharest 44
Brussels 33
Council Bluffs 33
Rome 32
Des Moines 28
Houston 28
Frankfurt am Main 27
Brooklyn 26
Dallas 26
Dearborn 26
Nuremberg 25
Redmond 25
Tokyo 25
Foligno 23
Orem 23
Vienna 23
Shanghai 22
Tashkent 22
Warsaw 22
Amsterdam 21
Hefei 21
Mexico City 21
Belo Horizonte 20
London 20
San Paolo di Civitate 20
Montreal 19
Rio de Janeiro 19
Norwalk 18
Chennai 17
Redwood City 17
Barnet 16
Assisi 15
Atlanta 15
Haiphong 15
San Francisco 15
Izmir 14
Milan 14
Saint Petersburg 14
Stockholm 14
Baghdad 13
Chicago 13
Denver 13
Johannesburg 13
Manchester 13
Toronto 13
Ankara 12
Guangzhou 12
Menlo Park 12
Mumbai 12
Phoenix 12
Amman 11
Brno 11
Falkenstein 9
Istanbul 9
Paris 9
Poplar 9
Woodbridge 9
Collazzone 8
Falls Church 8
Jakarta 8
Manila 8
Tianjin 8
Abidjan 7
Addis Ababa 7
Baku 7
Bangkok 7
Boston 7
Totale 8.231
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 179
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 178
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 176
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 174
BCOR gene alterations in hematological diseases 160
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 159
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 159
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 158
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 154
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 150
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 143
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 139
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 134
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 130
Mutant NPM1 Maintains the Leukemic State through HOX Expression 129
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 129
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 129
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 129
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 128
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 126
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 126
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 126
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 126
Mesenchymal cells: a vehicle for gene therapy 123
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 119
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 119
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 117
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 116
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 115
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 114
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 113
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 110
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 110
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 109
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 109
T regulatory cell separation for clinical application. 109
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 109
BRAF mutations in hairy-cell leukemia. 108
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 108
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 108
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 108
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 107
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 107
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 107
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 107
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 105
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 105
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 104
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 104
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 104
Richter's transformation in the heart 104
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 100
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 99
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 99
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 98
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 95
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 95
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 95
Functions of the native NPM1 protein and its leukemic mutant 92
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 92
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 91
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 90
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 90
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 90
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 89
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 89
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 89
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 88
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 88
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 88
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect 86
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 86
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 84
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 83
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 83
Mesenchymal cells recruit and regulate T regulatory cells. 83
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 80
NPM1-mutated acute myeloid leukemia: from bench to bedside 80
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 79
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 79
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 77
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 77
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 75
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 75
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 73
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 72
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 72
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 71
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 70
A scale of "bad" co-mutations in NPM1-driven AML 70
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 67
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 67
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 67
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 66
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study 65
The landscape of BRAF transcript and protein variants in human cancer. 65
NOTCH and Graft-Versus-Host Disease 65
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 64
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 64
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 64
Totale 10.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.388
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.388
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021206 0 0 0 0 0 0 0 0 0 21 35 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20252.398 77 195 63 81 293 142 211 172 478 109 366 211
2025/20264.955 360 303 237 597 741 482 902 324 554 455 0 0
Totale 12.933